2016 Clinical Development Protein Production 
Codon
MARCH 24, 2024
Once approved, patent-protected drugs are the highest-margin physical products on the planet—even with the high price of bioreactors. The real cost is clinical development. In 2012, an Israeli company called Protalix gained approval for their plant-based enzyme product for Gaucher’s disease. Why rock the boat?
The Pharma Data
JANUARY 24, 2021
” About Elasmogen: Spun-out from the University of Aberdeen, Scotland in 2016, Elasmogen is developing soloMERs ; fully humanized (or de-immunised) VNAR, as next generation, single chain therapeutics for auto-inflammatory diseases, oncology and intracellular delivery.
Expert insights. Personalized for you.
84 
Let's personalize your content